SFE Investment Counsel Reduces Position in Pfizer Inc. (NYSE:PFE)

SFE Investment Counsel decreased its holdings in shares of Pfizer Inc. (NYSE:PFE) by 37.8% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 79,104 shares of the biopharmaceutical company’s stock after selling 48,165 shares during the quarter. SFE Investment Counsel’s holdings in Pfizer were worth $2,277,000 as of its most recent SEC filing.

Other large investors have also modified their holdings of the company. Worth Asset Management LLC purchased a new stake in shares of Pfizer in the first quarter valued at about $29,000. Briaud Financial Planning Inc purchased a new stake in shares of Pfizer in the third quarter valued at about $30,000. GoalVest Advisory LLC grew its holdings in shares of Pfizer by 304.9% in the fourth quarter. GoalVest Advisory LLC now owns 1,077 shares of the biopharmaceutical company’s stock valued at $31,000 after purchasing an additional 811 shares during the period. Mizuho Securities Co. Ltd. purchased a new stake in shares of Pfizer in the third quarter valued at about $34,000. Finally, VisionPoint Advisory Group LLC grew its holdings in shares of Pfizer by 52,350.0% in the third quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company’s stock valued at $35,000 after purchasing an additional 1,047 shares during the period. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Price Performance

NYSE:PFE traded down $0.09 during mid-day trading on Thursday, reaching $25.33. 26,574,240 shares of the stock were exchanged, compared to its average volume of 42,343,496. The business has a fifty day moving average price of $27.19 and a 200 day moving average price of $28.76. The firm has a market capitalization of $143.43 billion, a PE ratio of 70.25, a PEG ratio of 1.16 and a beta of 0.61. Pfizer Inc. has a 1-year low of $25.23 and a 1-year high of $40.56. The company has a current ratio of 0.91, a quick ratio of 0.69 and a debt-to-equity ratio of 0.69.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.29. Pfizer had a return on equity of 10.88% and a net margin of 3.62%. The business had revenue of $14.25 billion during the quarter, compared to analyst estimates of $14.37 billion. During the same quarter last year, the company posted $1.14 EPS. Pfizer’s revenue for the quarter was down 41.3% on a year-over-year basis. Research analysts expect that Pfizer Inc. will post 2.24 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms have commented on PFE. TD Cowen cut shares of Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 target price on the stock. in a research report on Thursday, January 4th. Argus lowered Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. Cantor Fitzgerald reissued an “overweight” rating and set a $45.00 price target on shares of Pfizer in a research report on Monday. Finally, Guggenheim started coverage on Pfizer in a research note on Friday, February 23rd. They set a “buy” rating and a $36.00 price objective for the company. Twelve analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $36.88.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.